Skip to main content

Table 3 Association of H3K27me3 expression (85% cut-off) with clinicopathological features

From: Digital imaging-assisted quantification of H3K27me3 immunoexpression in luminal A/B-like, HER2-negative, invasive breast cancer predicts patient survival and risk of recurrence

VariablesH3K27me3 “low” expression (<  85%) N(%)H3K27me3 “high” expression (≥ 85%) N(%)P value
Number of cases74 (46.3%)86 (53.7%) 
Median age
 < 61 years old37 (50%)39 (45.3%)0.557
 ≥ 61 years old37 (50%)47 (54.7%) 
Luminal subtype
 Luminal A-like31 (41.9%)35 (40.7%)0.878
 Luminal B-like43 (58.1%)51 (59.3%) 
Pathological tumor size
 ≤ 2 cm (pT1)26/71 (36.6%)29/77 (37.7%)0.817
 > 2 cm (pT2–4)45/71 (63.4%)48/77 (62.3%) 
Pathological nodal status
 N029/73 (39.7%)39/80 (48.8%)0.262
 N+ (N1–3)44/73 (60.3%)41/80 (51.2%) 
Grade
 1 or 243/74 (58.1%)62/86 (72.1%)0.069
 331/74 (41.9%)24/86 (27.9%) 
Histology
 IDC62 (83.8%)71 (82.6%)0.836
 Other subtypes12 (16.2%)15 (17.4%) 
Adjuvant chemotherapy
 CT29/43 (67.4%)34/57 (59.6%)0.424
 No CT14/43 (32.6%)23/57 (40.4%) 
Adjuvant endocrine therapy
 TMX only45/60 (75%)48/68 (70.6%)0.576
 TMX + AI15/60 (25%)19/68 (27.9%) 
  1. Abbreviations: AI Aromatase inhibitor, CT Chemotherapy, IDC Invasive ductal carcinoma, TMX Tamoxifen